Related Experiment Video
Updated: Jun 13, 2026

Isolation of Fidelity Variants of RNA Viruses and Characterization of Virus Mutation Frequency
Published on: June 16, 2011
Influence of Different Inactivation Methods on Severe Acute Respiratory Syndrome Coronavirus 2 RNA Copy Number
Hailong Chen1, Rui Wu1, Yuan Xing2
1Xi'an Center for Disease Control and Prevention, Xi'an, Shaanxi, China.
Abstract:
The outbreak of coronavirus disease 2019 (COVID-19) has spread across the world and was characterized as a pandemic. To protect medical laboratory personnel from infection, most laboratories inactivate the virus causing COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in clinical samples before testing. However, the effect of inactivation on the detection results remains unknown. Here, we used a digital PCR assay to determine the absolute SARS-CoV-2 RNA copy number in 63 nasopharyngeal swab samples and assess the effect of inactivation methods on viral RNA copy number. Viral inactivation was performed by three different methods: (i) incubation with the TRIzol LS reagent for 10 min at room temperature, (ii) heating in a water bath at 56°C for 30 min, and (iii) high-temperature treatment, including autoclaving at 121°C for 20 min, boiling at 100°C for 20 min, and heating at 80°C for 20 min. Compared to the amount of RNA in the original sample, TRIzol treatment destroyed 47.54% of the nucleocapsid protein (N) gene and 39.85% of open reading frame (ORF) 1ab. For samples treated at 56°C for 30 min, the copy number of the N gene and ORF 1ab was reduced by 48.55% and 56.40%, respectively. The viral RNA copy number dropped by 50 to 66% after heating at 80°C for 20 min. Nearly no viral RNA was detected after autoclaving at 121°C or boiling at 100°C for 20 min. These results indicate that inactivation reduced the quantity of detectable viral RNA and may cause false-negative results, especially in weakly positive cases. Thus, use of the TRIzol reagent rather than heat inactivation is recommended for sample inactivation, as the TRIzol reagent had the least effect on the RNA copy number among the tested methods.
Insights
Inactivating SARS-CoV-2 with heat or TRIzol LS reagent reduces viral RNA copy number, potentially causing false negatives. TRIzol LS reagent showed the least impact on RNA quantity, making it a recommended method for sample inactivation.
Area of Science:
- Virology
- Molecular Biology
- Clinical Diagnostics
Background:
- The COVID-19 pandemic necessitates stringent safety measures in medical laboratories.
- Inactivation of SARS-CoV-2 in clinical samples is crucial for protecting laboratory personnel.
- The impact of different inactivation methods on SARS-CoV-2 RNA detection remains unclear.
Purpose of the Study:
- To assess the effect of various inactivation methods on SARS-CoV-2 RNA copy number.
- To compare the efficacy of TRIzol LS reagent and heat-based inactivation methods.
- To determine the optimal inactivation method to minimize RNA degradation for accurate testing.
Main Methods:
- Digital PCR was used to quantify absolute SARS-CoV-2 RNA copy numbers in nasopharyngeal swab samples.
- Three inactivation methods were tested: TRIzol LS reagent, 56°C heat, and high-temperature treatments (80°C, 100°C, 121°C).
- Viral RNA copy numbers were measured before and after each inactivation procedure.
Main Results:
- TRIzol LS reagent treatment reduced N gene and ORF 1ab RNA by 47.54% and 39.85%, respectively.
- 56°C heat treatment reduced N gene and ORF 1ab RNA by 48.55% and 56.40%, respectively.
- High-temperature treatments (80°C, 100°C, 121°C) caused significant RNA degradation, with near-complete loss after autoclaving or boiling.
Conclusions:
- Sample inactivation methods significantly reduce detectable SARS-CoV-2 RNA levels.
- Heat inactivation, especially at higher temperatures, leads to substantial RNA loss and potential false-negative results.
- TRIzol LS reagent is recommended for SARS-CoV-2 sample inactivation due to its minimal impact on viral RNA quantity.
Related Concept Videos
Coronavirus
Inhibitors Of Virion Release

